J Drugs Dermatol. 2023 Oct 1;22(10):994-1000. doi: 10.36849/JDD.7701.
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. The unique mechanism of action of brodalumab, which blocks signaling mediated by multiple IL-17 family members, may play a key role in the overall efficacy, including in patients whose disease did not respond to other biologics. In this narrative review, we discuss the mechanism of action of brodalumab in inflammatory skin conditions, exploring how it relates to clinical and real-world efficacy, rescued responses after IL-17A inhibitor failure, and improvements in mental health and quality of life. J Drugs Dermatol. 2023;22(10):994-1000 doi:10.36849/JDD.7701.
生物制剂疗法被用于治疗多种炎症性疾病的系统性治疗，包括中重度斑块型银屑病。布罗达umab 是一种白细胞介素-17（IL-17）受体 A 拮抗剂，适用于中重度斑块型银屑病成年患者，这些患者适合全身治疗或光疗，且对其他全身治疗无应答或已失去应答。布罗达umab 的独特作用机制，即阻断多种 IL-17 家族成员介导的信号传导，可能在整体疗效中发挥关键作用，包括对其他生物制剂无应答的患者。在这篇叙述性综述中，我们讨论了布罗达umab 在炎症性皮肤疾病中的作用机制，探讨了它与临床和真实世界疗效、IL-17A 抑制剂失败后的挽救应答以及心理健康和生活质量改善的关系。J 皮肤病药物学杂志。2023;22(10):994-1000 doi:10.36849/JDD.7701.
